Effects of the hepatocarcinogenic peroxisome-proliferating hypolipidemic agents clofibrate and nafenopin on the rat liver cell membrane enzymes gamma-glutamyltranspeptidase and alkaline phosphatase and on the early stages of liver carcinogenesis
- PMID: 6149819
- DOI: 10.1093/carcin/5.12.1603
Effects of the hepatocarcinogenic peroxisome-proliferating hypolipidemic agents clofibrate and nafenopin on the rat liver cell membrane enzymes gamma-glutamyltranspeptidase and alkaline phosphatase and on the early stages of liver carcinogenesis
Abstract
The effects of the hepatocarcinogenic peroxisome proliferating hypolipidemic agents clofibrate (CF) and nafenopin (NF) on rat liver carcinogenesis initiated by N-2-fluorenylacetamide (FAA) were studied and compared with that of the neoplasm promoter phenobarbital (PB). Male F344 rats were fed 0.02% FAA for 8 weeks to induce hepatocellular altered foci, and were then given no chemical or equimolar amounts (0.03 mmol/kg diet) of the chemicals for 24 weeks in the diet. In groups of animals killed sequentially, 0.07% PB had a marked enhancing effect on FAA-induced foci, while 0.073% CF produced only slight enhancement and 0.093% NF produced none. At the end of the experiment, only PB increased the incidence and multiplicity of liver neoplasms. NF suppressed histochemical gamma-glutamyltranspeptidase activity in the abnormal hepatocytes of foci as well as in periportal hepatocytes. In homogenates of livers from rats fed NF, gamma-glutamyl-transpeptidase activity was reduced, and this occurred to a lesser degree with CF, whereas PB enhanced activity. NF also induced alkaline phosphatase activity in hepatocytes throughout the lobule, but not in altered hepatocytes, thereby making foci demonstrable in sections reacted for alkaline phosphatase. These findings thus reveal significant cell membrane effects of NF and CF and suggest that their involvement in hepatocarcinogenesis is more complex than a promoting action.
Similar articles
-
Effects of the hepatocarcinogen nafenopin, a peroxisome proliferator, on the activities of rat liver glutathione-requiring enzymes and catalase in comparison to the action of phenobarbital.Cancer Res. 1985 Oct;45(10):5011-9. Cancer Res. 1985. PMID: 2862989
-
Tumor promotion by the peroxisome proliferator nafenopin involving a specific subtype of altered foci in rat liver.Cancer Res. 1990 Jun 15;50(12):3701-8. Cancer Res. 1990. PMID: 1971196
-
Absence of a promoting or sequential syncarcinogenic effect in rat liver by the carcinogenic hypolipidemic drug nafenopin given after N-2-fluorenylacetamide.Toxicol Appl Pharmacol. 1985 Jan;77(1):76-85. doi: 10.1016/0041-008x(85)90269-8. Toxicol Appl Pharmacol. 1985. PMID: 3966244
-
An overview of peroxisome proliferator-induced hepatocarcinogenesis.Environ Health Perspect. 1991 Jun;93:205-9. doi: 10.1289/ehp.9193205. Environ Health Perspect. 1991. PMID: 1685443 Free PMC article. Review.
-
Hepatocarcinogenesis of peroxisome proliferators.Ann N Y Acad Sci. 1996 Dec 27;804:573-87. doi: 10.1111/j.1749-6632.1996.tb18646.x. Ann N Y Acad Sci. 1996. PMID: 8993574 Review. No abstract available.
Cited by
-
Promoting effect of the peroxisome proliferator, clofibrate, but not di(2-ethylhexyl)phthalate, on urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.Jpn J Cancer Res. 1990 Dec;81(12):1232-8. doi: 10.1111/j.1349-7006.1990.tb02684.x. Jpn J Cancer Res. 1990. PMID: 2125992 Free PMC article.
-
Enzymes of glutathione metabolism as biochemical markers during hepatocarcinogenesis.Cancer Metastasis Rev. 1987;6(2):155-78. doi: 10.1007/BF00052847. Cancer Metastasis Rev. 1987. PMID: 2885099 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous